Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure

被引:88
|
作者
Mortara, A [1 ]
La Rovere, MT [1 ]
Pinna, GD [1 ]
Maestri, R [1 ]
Capomolla, S [1 ]
Cobelli, F [1 ]
机构
[1] IRCCS, Ctr Med Montescano, S Maugeri Fdn, Div Cardiol,Dept Cardiol, Pavia, Italy
关键词
D O I
10.1016/S0735-1097(00)00900-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The purpose of this study was to investigate in a case-controlled study whether carvedilol increased baroreflex sensitivity and heart rate variability (HRV). BACKGROUND In chronic heart failure (CHF), beta-adrenergic blockade improves symptoms and ventricular function and may favorably affect prognosis. Although beta-blockade therapy is supposed to decrease myocardial adrenergic activity, data on restoration of autonomic balance to the heart and, particularly, on vagal reflexes are limited. METHODS Nineteen consecutive patients with moderate, stable CHF (age 54 +/- 7 years, New York Heart Association [NYHA] class II to III, left ventricular ejection fraction [LVEF] 24 +/- 6%), treated with optimized conventional medical therapy, received carvedilol treatment. Controls with CHF were selected from our database on the basis of the following matching criteria: age +/- 3 years, same NYHA class, LVEF +/- 346, pulmonary wedge pressure +/- 3 mm Hg, peak volume of oxygen +/- 3 ml/kg/min, same therapy. All patients underwent analysis of baroreflex sensitivity (phenylephrine method) and of HRV (24-h Holter recording) at baseline and after six months. RESULTS Beta-blockade therapy was associated with a significant improvement in symptoms (NYHA class 2.1 +/- 0.4 vs. 1.8 +/- 0.5, p < 0.01), systolic and diastolic function (LVEF 23 +/- 7 vs. 28 +/- 9%, p < 0.01; pulmonary wedge pressure 17 +/- 8 vs. 14 +/- 7 mm Hg, p < 0.05) and mitral regurgitation area (7.0 +/- 5.1 vs. 3.6 +/- 3.0 cm(2), p < 0.01). No significant differences were observed in either clinical or hemodynamic indexes in control patients. Phenylephrine method increased significantly after carvedilol (from 3.7 +/- 3.4 to 7.1 +/- 4.9 ms/mm Hg, p < 0.01) as well as RR interval (from 791 +/- 113 to 894 +/- 110 ms, p < 0.001), 24-h standard deviation of normal RR interval and root mean square of successive differences (from 56 +/- 17 to 80 +/- 28 ms and from 12 +/- 7 to 18 +/- 9 ms, all p < 0.05), while all parameters remained unmodified in controls. During a mean follow-up of 19 +/- 8 months a reduced number of cardiac events (death plus heart transplantation, 58% vs. 31%) occurred in those patients receiving beta-blockade. CONCLUSIONS Besides the well-known effects on ventricular function, treatment with carvedilol in CHF restores both autonomic balance and the ability to increase reflex vagal activity. This protective mechanism may contribute to the beneficial effect of beta-blockade treatment on prognosis in CHF. (C) 2000 by the American College of Cardiology.
引用
收藏
页码:1612 / 1618
页数:7
相关论文
共 50 条
  • [1] Focus on carvedilol: A novel beta-adrenergic blocking agent for the treatment of congestive heart failure
    Chen, BP
    Chow, MSS
    [J]. FORMULARY, 1997, 32 (08) : 795 - +
  • [2] Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure
    Demopoulos, L
    Yeh, M
    Gentilucci, M
    Testa, M
    Bijou, R
    Katz, SD
    Mancini, D
    Jones, M
    LeJemtel, TH
    [J]. CIRCULATION, 1997, 95 (07) : 1764 - 1767
  • [3] Hypertension, heart failure, and beta-adrenergic blocking drugs
    Fowler, Michael B.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (13) : 1073 - 1075
  • [4] Beta-Adrenergic Blockers for Chronic Heart Failure
    Javed, Usman
    Deedwania, Prakash C.
    [J]. CARDIOLOGY IN REVIEW, 2009, 17 (06) : 287 - 292
  • [5] Beta-adrenergic blockade in chronic heart failure
    Martínez, JM
    [J]. MEDICINA-BUENOS AIRES, 1999, 59 (06) : 793 - 797
  • [6] Effect of beta-adrenergic blocker therapy on the circadian rhythm of heart rate variability in patients with chronic stable angina pectoris
    Burger, AJ
    Kamalesh, M
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (04): : 596 - 598
  • [7] Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients
    Petersen, Morten
    Andersen, Jon T.
    Hjelvang, Brian R.
    Broedbaek, Kasper
    Afzal, Shoaib
    Nyegaard, Mette
    Borglum, Anders D.
    Stender, Steen
    Kober, Lars
    Torp-Pedersen, Christian
    Poulsen, Henrik E.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (04) : 556 - 565
  • [8] Beta-adrenergic blockers in chronic congestive heart failure
    Smith, AJ
    Manley, HJ
    Richardson, AD
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (05) : 469 - 469
  • [9] Effects of beta-adrenergic blockade on survival of patients with chronic heart failure
    Packer, M
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (11A): : L46 - L54
  • [10] Biventricular pacing improves heart rate variability in patients with chronic heart failure
    Kramm, B
    Mortensen, P
    Bruns, HJ
    Linde, C
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 : 29 - 29